March 7th 2022May 11th 2020 Shorla Oncology Irish Pharmaceutical startup-Tipperary Read more at: https://www.siliconrepublic.com/start-ups/shorla-pharma-irish-pharmaceutical-startup-tipperary
Sharon Cunningham & Orlaith Ryan are 2024 EY Entrepreneur Of The Year FinalistsApril 19th 2024Read More Sharon Cunningham & Orlaith Ryan are 2024 EY Entrepreneur Of The Year Finalists
Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other CancersApril 8th 2024Read More Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers
We are delighted to be attending the HOPA 2024 conference at Tampa Florida from 3-6 April. We are looking forward to meeting you at Booth #620.March 26th 2024Read More We are delighted to be attending the HOPA 2024 conference at Tampa Florida from 3-6 April. We are looking forward to meeting you at Booth #620.
Shorla Oncology Achieves Great Place to Work CertificationMarch 26th 2024Read More Shorla Oncology Achieves Great Place to Work Certification
FDA Receives New Drug Application for SH-105 in Breast and Ovarian CancerJanuary 15th 2024Read More FDA Receives New Drug Application for SH-105 in Breast and Ovarian Cancer
OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian CancerJanuary 15th 2024Read More OncLive/ SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer
Targeted Oncology/ FDA Ok’s NDA for SH-105 in Breast and Ovarian CancerJanuary 15th 2024Read More Targeted Oncology/ FDA Ok’s NDA for SH-105 in Breast and Ovarian Cancer
Pharmaceutical Executive/ FDA Accepts New Drug Application for Shorla Oncology’s Novel Treatment for Breast, Ovarian CancerJanuary 12th 2024Read More Pharmaceutical Executive/ FDA Accepts New Drug Application for Shorla Oncology’s Novel Treatment for Breast, Ovarian Cancer
Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for novel formulation to treat breast and ovarian cancerJanuary 9th 2024Read More Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for novel formulation to treat breast and ovarian cancer